From GlobeNewswire:

X4 Pharmaceuticals issued 1,524,112 stock options to new employees under the 2019 Inducement Equity Incentive Plan on February 29, 2024. The options have a 10-year term with an exercise price of $0.9710 per share and will vest over a four-year period, subject to continued employment with X4. The company’s lead clinical candidate, mavorixafor, is being developed as an oral therapy for rare immune system diseases like WHIM syndrome. X4 Pharmaceuticals is currently planning a Phase 3 clinical program for mavorixafor in chronic neutropenic disorders. Contacts for investors and media are available for more information.



Read more at GlobeNewswire: X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq